Prognostic factors for achievement of CR and survival
| . | Total n . | CR* . | P . | n . | Survival† . | P . |
|---|---|---|---|---|---|---|
| Total | 224 | 94 (42%) | 291 | 29% ± 3% | ||
| Sex | ||||||
| Male | 141 | 59 (42%) | > .05 | 181 | 30% ± 4% | > .05 |
| Female | 83 | 36 (43%) | 110 | 26% ± 5% | ||
| Age, y | ||||||
| 15-25 | 75 | 40 (53%) | .06 | 107 | 38% ± 5% | < .0001 |
| 26-45 | 109 | 41 (38%) | .02§ | 129 | 28% ± 4% | |
| 46-55 | 49 | 14 (35%) | 55 | 12% ± 5% | ||
| WBCs/μL‡ | ||||||
| < 30 000 | 146 | 68 (47%) | > .05 | 201 | 29% ± 4% | > .05 |
| > 30 000 | 72 | 25 (35%) | 81 | 28% ± 5% | ||
| Risk group‡ | ||||||
| Standard | 164 | 74 (45%) | > .05 | 217 | 32% ± 4% | .01 |
| High | 60 | 21 (35%) | 74 | 20% ± 5% | ||
| Subtype | ||||||
| B-lineage | 159 | 73 (46%) | > .05 | 215 | 29% ± 3% | > .05 |
| T-lineage | 65 | 22 (34%) | 76 | 30% ± 6% | ||
| Subtype (detail) | ||||||
| C/pre-B | 150 | 72 (48%) | > .05 | 201 | 31% ± 4% | > .05 |
| Pro B | 9 | 1 (11%) | 14 | 0% | ||
| Early T | 9 | 3 (33%) | 11 | 9% ± 9% | ||
| Mature T | 11 | 2 (18%) | 12 | 17% ± 11% | ||
| Thymic T | 44 | 17 (39%) | 52 | 38% ± 7% | ||
| Time to relapse, mo | ||||||
| < 18 | 160 | 58 (36%) | .003 | 200 | 22% ± 3% | < .0001 |
| > 18 | 64 | 37 (58%) | 91 | 43% ± 6% | ||
| Response to first salvage | ||||||
| CR | 95 | 47% ± 6% | < .0001 | |||
| No CR | 129 | 13% ± 3% | ||||
| Response to second salvage‡ | ||||||
| CR | 27 | 35% ± 9% | .0003 | |||
| No CR | 55 | 8% ± 4% |
| . | Total n . | CR* . | P . | n . | Survival† . | P . |
|---|---|---|---|---|---|---|
| Total | 224 | 94 (42%) | 291 | 29% ± 3% | ||
| Sex | ||||||
| Male | 141 | 59 (42%) | > .05 | 181 | 30% ± 4% | > .05 |
| Female | 83 | 36 (43%) | 110 | 26% ± 5% | ||
| Age, y | ||||||
| 15-25 | 75 | 40 (53%) | .06 | 107 | 38% ± 5% | < .0001 |
| 26-45 | 109 | 41 (38%) | .02§ | 129 | 28% ± 4% | |
| 46-55 | 49 | 14 (35%) | 55 | 12% ± 5% | ||
| WBCs/μL‡ | ||||||
| < 30 000 | 146 | 68 (47%) | > .05 | 201 | 29% ± 4% | > .05 |
| > 30 000 | 72 | 25 (35%) | 81 | 28% ± 5% | ||
| Risk group‡ | ||||||
| Standard | 164 | 74 (45%) | > .05 | 217 | 32% ± 4% | .01 |
| High | 60 | 21 (35%) | 74 | 20% ± 5% | ||
| Subtype | ||||||
| B-lineage | 159 | 73 (46%) | > .05 | 215 | 29% ± 3% | > .05 |
| T-lineage | 65 | 22 (34%) | 76 | 30% ± 6% | ||
| Subtype (detail) | ||||||
| C/pre-B | 150 | 72 (48%) | > .05 | 201 | 31% ± 4% | > .05 |
| Pro B | 9 | 1 (11%) | 14 | 0% | ||
| Early T | 9 | 3 (33%) | 11 | 9% ± 9% | ||
| Mature T | 11 | 2 (18%) | 12 | 17% ± 11% | ||
| Thymic T | 44 | 17 (39%) | 52 | 38% ± 7% | ||
| Time to relapse, mo | ||||||
| < 18 | 160 | 58 (36%) | .003 | 200 | 22% ± 3% | < .0001 |
| > 18 | 64 | 37 (58%) | 91 | 43% ± 6% | ||
| Response to first salvage | ||||||
| CR | 95 | 47% ± 6% | < .0001 | |||
| No CR | 129 | 13% ± 3% | ||||
| Response to second salvage‡ | ||||||
| CR | 27 | 35% ± 9% | .0003 | |||
| No CR | 55 | 8% ± 4% |
Patients with relapse during or after chemotherapy and without Ph+/BCR-ABL+ ALL or CNS involvement.
CR rates were calculated for 224 patients with data on their response to first salvage therapy.
Survival rates are shown as probability of survival ± SD at 3 years.
At first diagnosis.
CR rates in patients younger and older than 25 years: 53% versus 37%, respectively.
¶Calculated for 82 patients with data on their response to second salvage therapy.